Abstract
Background and Aims Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most invalidating
secondary effects (60%) both of colorectal cancer as well as breast cancer and is
a reason for abandoning medical treatment. The symptoms are based on pain, tingling,
numbness, and can affect quality of sleep. It is known that analgesia induced by TENS
is multifactorial and probably comprises peripheral, spinal and supraspinal mechanisms.
Besides, these effects could be greater if the application is performed percutaneously.
Therefore, the principal aim of this study was to evaluate the effectiveness of ultrasound-guide
percutaneous neuromodulation on the quality of life of patients who suffer CIPN.
Material and Methods Three patients (n = 2 breast cancer and n = 1 colorectal cancer) were recruited from
the University Hospital Virgen de las Nieves (Granada, Spain). This study received
ethics committee approval (0110-N-18) The radial, cubital and median nerves were treated
in the upper limb, and the tibial, peroneal, sural and saphenous nerves were treated
for the lower limb. In total, eight treatment sessions were performed per affected
limb, using the treatment protocol of NMP® (20 seconds of TENS 10Hz 2mA and 10 minutes of TENS 2Hz 1-10mA and in the sural nerve.
Besides, 5 minutes of TENS was applied TENS 50Hz 1-10mA) in a weekly session during
two months. Before and after treatment, the following variables were evaluated: 1)
neuropathy specific quality of life (EORTC QLQ-CIPN20) consisting of three subscales
(0-100): sensory, autonomic, motor (greater conduction); 2) intensity of symptoms
(numbness, pain and tingling) using the visual analog scale (VAS) (0-10); and 3) sleep
according to the Pittsburgh Sleep Quality Index (0-21) using its total component.
For the analyses, the normality of the population was assumed due to the nature of
the study (N = 3) and therefore the Student's t-test was used to analyze the differences
in the baseline and post-intervention means using the IBM SPSS Statistics 21 software
(IBM Corporation, Armonk, NY).
Results Regarding the autonomic subscale (baseline mean, SD 38.89 ± 5.56) of the EORTC QLQ-CIPN20
the difference of means was statistically significant (-38.89 ± 9.62) (t = -6.99;
P = 0.020). The remaining subscales were not significant (P > 0.05) despite the fact
that the results also improved: sensory (-2.47 + -16.7); motor (-26.89 ± 19.25); and
conduction (-11.11 ± 19.25). The VAS for pain (baseline mean, SD: 5 ± 2.52) obtained
a difference in means of −1.67 ± 2.08, although it was not significant (P > 0.05)
it did reach a clinically relevant difference (1.1 points). For the remaining VAS
scales, numbing and tingling, no statistically significant differences were obtained
−1.17 ± 2.021 and −1.5 ± 1.80, respectively (P > 0.05). Lastly, the Pittsburgh questionnaire
(baseline mean: 10) decreased by −3.67 ± 1.53 showing a trend towards significance
(t = -4.19; P= 0,053).
Conclusion Despite this being a pilot study, percutaneous neuromodulation is shown to improve
the symptoms of neuropathy induced by chemotherapy, specifically autonomic symptoms
and quality of sleep. Our results may represent a change of paradigm in physical therapy
treatment.
